This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2011 Remove Government Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

NOVEMBER 14, 2023

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. The price is available to cash-paying patients with a valid prescription. References: 1.

Retail 52
Retail Pharmaceutical manufacturing Sales Insurance 52
article thumbnail

Everything You Need to Know About Market Access in China

PM360

DECEMBER 20, 2023

At the same time, a “drug lag” persists in China for global pharmaceutical companies’ products. Furthermore, the Chinese government maintains its support for local manufacturers to bridge the gap left by innovative foreign drugs or to substitute them with more cost-effective local alternatives. billion people in 2023).

Marketing 105
Marketing Insurance Medical Manufacturing 105
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024